Rituximab in CD20 positive multiple myeloma

In the letter of Moreau, the result of a small trial of the treatment with rituximab as a single agent in patients with multiple myeloma (MM) that expresses CD20 is reported. In this trial, there is no benefit for the patients newly diagnosed or relapsed with CD20þ MM. In a later letter of Gozzetti, complete remission is reported in a single patient with… CONTINUE READING